GlassScriptPhysician profile
Melia Mcmanus
NPI 1568811677
$4,919.00
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $758 · 2022: $3,062 · 2023: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,099.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,657.60 | 2022-2023 | Wavewriter Alpha Prime 16, Artisan |
| Abbvie INC. | $390.06 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $212.74 | 2022-2023 | Relistor |
| Spr Therapeutics, INC | $201.66 | 2022 | |
| Relievant Medsystems, INC. | $123.68 | 2022 | |
| Nevro Corp. | $113.59 | 2022-2023 | Senza |
| Lundbeck LLC | $82.57 | 2023 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $77.55 | 2022 | |
| Abbott Laboratories | $55.95 | 2023 | Proclaim |
| Allergan, INC. | $49.90 | 2022 | |
| Amgen INC. | $46.04 | 2022 | |
| Grt US Holding, INC. | $43.90 | 2022 | |
| Collegium Pharmaceutical, INC. | $43.46 | 2022-2023 | Xtampza |
| Amneal Pharmaceuticals LLC | $21.01 | 2023 | Lyvispah |
| Hikma Pharmaceuticals USA | $21.00 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $19.97 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melia Mcmanus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.